Lisa Bero - (Chair)
Lisa Bero is a professor in the School of Public Health and the School of Medicine (General Internal Medicine) at the University of Colorado CU Anschutz Medical Center. She is also the Chief Scientist at the Center for Bioethics and Humanities at that medical center. In addition, she is an affiliated professor at the Charles Perkins Centre and School of Pharmacy, Faculty of Medicine and Health at the University of Sydney. Dr. Bero is an adjunct professor in the Department of Clinical Pharmacy and Institute for Health Policy Studies at the University of California, San Francisco. She is recognized for her methodological studies on bias (including publication/reporting, design and funding biases) in the fields of clinical medicine (pharmaceuticals), tobacco control and environmental research, and on the use and implications of the evidence for prescribing decisions/policy. She investigates hidden biases in the design, conduct and publication of research. For more than 20 years, Dr. Bero has been actively involved in the Cochrane Collaboration, a global organization that summarizes the best evidence from research to help make informed choices about health care. She served as a member of the National Academies Board on Health Care Services; Committee to Review the IRIS Process, and Committee on Conflicts of Interest in Medical Research, Education, and Practice. Dr. Bero received a PhD in pharmacology from Duke University.
Hugh A. Barton
Hugh A. Barton is an independent consultant for applications of systems pharmacology and toxicology to drug discovery and safety evaluation or environmental risk assessment. He provides expert advice on physiologically based pharmacokinetic (PBPK) and pharmacodynamic (PD) models to address low-dose, interspecies, and inter-route extrapolations in estimating risks and their implementation for decision-making. Dr. Barton formerly was Associate Research Fellow with Biomedicine Design at Pfizer, Inc. for ten years. He focused on drug discovery by applying translational modeling and simulation to oncology, cardiovascular disease, and neurodegenerative diseases to assess PK, PD, and safety. Prior to that, he worked for US EPA for 9 years and several consulting companies. He was a member of the National Academies Committee on Inorganic Arsenic and the Committee to Evaluate the IRIS Protocol for Inorganic Arsenic. Dr. Barton currently serves as a member of EPA’s Science Advisory Board (SAB) and as chair of the SAB Chemical Assessment Advisory Committee. He received a PhD in toxicology from the Massachusetts Institute of Technology.
Weihsueh A. Chiu
Weihsueh A. Chiu is a professor in the Department of Veterinary Integrative Biosciences at the Texas A&M University. His research focuses on the development of quantitative, data-driven approaches for understanding and predicting the human health effects of environmental chemicals. Specifically, his research applies computational and statistical methods to transform data into knowledge used to protect public health. He also has an interest in approaches to estimate the variability in individual susceptibility to environmental exposures, so as to better protect sensitive subpopulations. Dr. Chiu currently serves on the National Academies Committee on Use of Emerging Science for Environmental Health Decisions. His previous service on National Academies committees includes the Committee on Endocrine-Related Low Dose Toxicity and the Committee on Predictive-Toxicology Approaches for Military Assessments of Acute Exposures. He received a PhD in physics from Princeton University.
Gary L. Ginsberg
Gary L. Ginsberg is director of the Center for Environmental Health within the New York State Department of Health and has a clinical professor appointment at the Yale School of Public Health. Previously, he was a state toxicologist in the Connecticut Department of Public Health Division of Environmental and Occupational Health Assessment. Dr. Ginsburg is involved in the use of toxicology and risk-assessment principles to evaluate human exposure to chemicals in air, water, soil, food, and the workplace. His published work includes the development and evaluation of physiologically based pharmacokinetic modeling for assessing risks from exposure to environmental agents, including neurotoxic effects, the interaction of lead and psycho-social stress, and developmental aspects of children. He served on several National Academies committees, including the Committee on Use of Emerging Science for Environmental Health Decisions, Committee on Inorganic Arsenic, Committee on Improving Risk Analysis Approaches Used by the U.S. EPA, and Committee on Human Biomonitoring for Environmental Toxicants. Dr. Ginsberg received a PhD in toxicology from the University of Connecticut.
Julie B. Herbstman is an associate professor in the Department of Environmental Health Sciences, director of the Columbia Center for Children's Environmental Health, and co-director of the Certificate Program in Molecular Epidemiology at the Columbia University Mailman School of Public Health. Her recent research work involves the integration of epigenetic biomarkers to explore the mechanistic pathway between prenatal exposures and disease risk. In addition, she has addressed the impact of prenatal exposures to environmental pollutants, including polybrominated diphenyl ethers (PBDEs) and polycyclic aromatic hydrocarbons (PAHs) on child growth and development. She has also been involved in research exploring the long-term environmental health impact of exposure to pollutants from the collapse of the World Trade Center on 9/11. Dr. Herbstman received a PhD in environmental epidemiology from the Johns Hopkins University.